PharmaSource Podcast

Life Science Networks
  • 0,0 (0)
  • Yaşam Bilimleri
  • Her Hafta

Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing. In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides. Make sure to subscribe for your regular dose of pharma insight.

  1. The Rezon Bio Story: Interview with Dr. Adriana Kiedzierska-Mencfeld

    23 sa. önce

    The Rezon Bio Story: Interview with Dr. Adriana Kiedzierska-Mencfeld

    At CDMO Live Europe 2026, Dr. Adriana Kiedzierska-Mencfeld, Chief Executive Officer of Rezon Bio, drew on 11 years of leading operations at Polpharma Biologics to explain why biosimilar developers must address cost strategy in process development, long before any product reaches market.

    22 dk.
  2. CMC Strategies Transforming Biologics Drug Development

    3 gün önce

    CMC Strategies Transforming Biologics Drug Development

    “CMC was not usually a core part of the planning — it was more of an afterthought. Now that funding has tightened, that is changing.” Siddhartha Jain, President of Shoolin Management Company, has spent two decades in biologics CMC across Novartis, Regeneron, Sanofi, and other major companies, contributing to the development and manufacturing of over 10 clinical and commercial molecules. In this episode of the PharmaSource podcast, Sid shares why raw material variability remains one of the industry’s most underestimated risks, what separates a technically proficient CDMO from one that is merely experienced, and why digital CMC transformation fails when it ignores people and process. Read the full article.

    36 dk.
  3. Strategic Procurement: How To Build Win-Win CDMO Alliances Beyond Price

    2 Tem

    Strategic Procurement: How To Build Win-Win CDMO Alliances Beyond Price

    At CDMO Live Europe 2025, a panel of procurement and commercial leaders argued that the most consequential CDMO negotiations happen after the contract is signed, covering risk-sharing structures, governance discipline, and the conditions under which trust compounds or collapses. The session was chaired by Matthew Holt, Co-Founder of Collaborative Sourcing, with panelists Salomon Engels, Head of External Manufacturing at Par Health; Mark Goemans, Chief Commercial Officer at Bora Biologics; and Thomas Thunnissen, Director of Procurement and Partnerships at Leyden Labs. The discussion moved through four stages of the partnership life cycle: initial negotiation, contract construction, governance, and risk-sharing. Read the full article here.

    45 dk.
  4. Tariffs, FDA Chaos, and BioSecure in Limbo: How CDMOs Should Operate Under Uncertainty

    25 Haz

    Tariffs, FDA Chaos, and BioSecure in Limbo: How CDMOs Should Operate Under Uncertainty

    Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA), walked CDMO Live Europe delegates through the full matrix of US policy pressures bearing on contract manufacturers, from Section 232 tariffs and most favored nation pricing to FDA workforce collapse and a stalled BioSecure Act. Read the full article here.

    45 dk.
  5. How Sandoz Cut Its Supplier Network by 34%: A Step-by-Step Consolidation Playbook

    25 Haz

    How Sandoz Cut Its Supplier Network by 34%: A Step-by-Step Consolidation Playbook

    At CDMO Live Europe 2026 Maik Talarczyk Head PMO External Supplier Operations, Sandoz, laid out the company’s three-year supplier network consolidation program, detailing a six-step make-vs-buy decision framework that reduced network complexity by 34% against its 2023 baseline. Maik Talarczyk opened with a warning. “The fan is always on – and the shit is always flying.” Sandoz entered 2024 managing approximately 500 finished dose form (FDF) suppliers — a network Talarczyk describes as fragmented and expensive to run. The initial diagnosis was that 20% of suppliers accounted for 80% of sales. But the structural problem ran deeper: commercial and technical operations weren’t talking to each other. Country organizations understood top-line sales and margin. They did not see what was happening in technical operations. Read the full article

    24 dk.
  6. We're joining Life Science Connect. Here's the story...

    23 Haz

    We're joining Life Science Connect. Here's the story...

    "We saw what you guys built and made a decision pretty quickly: we didn't want to compete with that. We wanted to be part of it." Jon Howland, CEO, Life Science Connect Today we are announcing that PharmaSource, CDMO Live and External Manufacturing Leaders will be joining forces with Life Science Connect to create a new events divison. In this special episode, Luke Bilton sits down with Life Science Connect CEO Jon Howland to talk about what's been going on behind the scenes, and what this new chapter means to biopharma outsourcing media and events. Read more on PharmaSource

    41 dk.
  7. Simtra BioPharma CCO: “Manufacturing in the Region for the Region Is Here to Stay”

    18 Haz

    Simtra BioPharma CCO: “Manufacturing in the Region for the Region Is Here to Stay”

    Mike Schaefers, Chief Operating Officer at Simtra BioPharma, outlined what it takes to build durable CDMO partnerships in injectable manufacturing, why regional supply chains have become a permanent feature, and how early-phase collaboration directly shortens time to market.

    14 dk.
  8. Closing the Biotech "Valley of Death": The Infrastructure Gap Holding Back Early-Stage Biologics Programs:

    14 Haz

    Closing the Biotech "Valley of Death": The Infrastructure Gap Holding Back Early-Stage Biologics Programs:

    "The challenge is not getting better biology. It's building a better system to carry the biology forward," says Richard van Rijnsoever. Debby Vermeer and Richard van Rijnsoever are co-founders of ExpediteBio, a Netherlands-based venture focused on accelerating antibody and protein therapeutics from discovery to first-in-human study. Debby also co-leads the biologics workstream at Oncode Accelerator, a national initiative working to accelerate cancer therapy development, e.g., by building infrastructure in the Netherlands. On the PharmaSource podcast, Debby and Richard spoke about the structural reasons biologics programs fail to reach patients, how their ASCEND framework addresses those failures, and what a more functional European biologics ecosystem could look like. Their conversation is a practical guide for biotech CEOs and CMC leaders navigating the most expensive stretch of early-stage drug development. Read more.

    29 dk.
Tümünü Görün (248)

Hakkında

Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing. In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides. Make sure to subscribe for your regular dose of pharma insight.

Bilgi

  • Yaratıcı
    Life Science Networks
  • Aktif Yıllar
    2023 - 2026
  • Bölümler
    248
  • Sınıflandırma
    Uygunsuz
  • Telif Hakkı
    © Life Science Networks
  • Şovun Web Sitesi
    PharmaSource Podcast

Beğenebilirsiniz